Welcome to Markets Desk, your midday read on what's moving markets and why.
Teva Pharmaceutical has closed its acquisition of Emalex Biosciences for seven hundred million dollars, with up to an additional two hundred million in commercial milestone payments. The deal centers on ecopipam, a treatment for Tourette syndrome, with an NDA filing planned for the second half of two thousand twenty six. It's a targeted specialty pharma bet as Teva continues rebuilding its pipeline.
Turning to tech, Coupang is absorbing a record fine out of South Korea — six hundred twenty four point seven billion won, roughly four hundred nine million dollars — levied by Seoul's Personal Information Protection Commission following a major data breach that spilled into a diplomatic dispute with Washington. For U.S. investors holding the New York-listed shares, this is a material regulatory hit that raises questions about governance and exposure in international markets.
And in the AI space, Palantir CEO Alex Karp didn't mince words on CNBC, telling the industry that AI leaders fundamentally don't understand how unlikeable they've become with the broader public. Karp's critique lands at a moment when trust in AI companies is under genuine scrutiny, and his willingness to say it aloud distinguishes Palantir's positioning from the rest of the sector.
That's the tape. Markets Desk, signing off the floor.
